Mallinckrodt PLC and Kremers Urban Pharmaceuticals Inc. could be gearing up for a fight with FDA, after the agency proposed withdrawing approval for the firms' generic forms of Janssen Pharmaceuticals Inc.'s ADHD medication Concerta (methylphenidate).
FDA concluded that Mallinckrodt's generic fails to provide "the same extent of methylphenidate exposure as CONCERTA during the 7- to...







